23andMe’s Former CEO Pushes Purchase Price Nearly $50 Million Higher

wsj.com/articles/23andmes-former-ceo-pushes-purchase-price-nearly-50-million-higher-7ec98421

23andMe has a path to a higher purchase price than the $256 million offered by biotech giant Regeneron after the genetic-testing company’s former chief executive pushed a bankruptcy court to reopen its sale process.

This story appeared on wsj.com, 2025-06-05 01:41:00.
The Entire Business World on a Single Page. Free to Use →